CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 443 enrolled
Drug / intervention
Arformoterol tartrate inhalation solution +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00250679
NCT00250679Phase 3Completed
CompareCT.gov

Multicenter, Double-Blind, Double-Dummy, Randomized, Active-Controlled, Parallel Group Long-Term Safety Study of 15 μg and 25 μg Arformoterol Tartrate Inhalation Solution BID in Subjects With Chronic Obstructive Pulmonary Disease

Sumitomo Pharma America, Inc.·interventional·Posted Nov 8, 2005·Updated Jun 4, 2012

In Brief

A Phase 3 clinical trial evaluating Arformoterol tartrate inhalation solution, Arformoterol 25 ųg BID, and 2 other interventions for Chronic Obstructive Pulmonary Disease and 2 related conditions. Completed, enrolled 443 participants across 60 sites.

Detailed Summary

To evaluate the long-term safety and monitor the long-term efficacy of arformoterol over a period of 6 months in subjects with chronic obstructive pulmonary disease (COPD).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsChronic Obstructive Pulmonary Disease, Bronchitis, Emphysema
CountriesUnited States
Collaborators--

Timeline

Phase 3CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedNov 8, 2005
Enrollment StartOct 1, 2005
Primary CompletionOct 1, 2007
TodayJul 2, 2026
Enrollment to primary: 2 yearsPosted 20.7 years ago

Interventions

Arformoterol tartrate inhalation solutiondrug

Arformoterol 15 ųg BID by nebulization

Arformoterol 25 ųg BIDdrug

Arformoterol 25 ųg BID by nebulization

Formoterol 12 ųg BIDdrug

Formoterol fumarate 12 ųg BID via aerolizer/DPI

Placebodrug

Placebo nebule or placebo aerolizer